Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Operations: 2011-2024

Historic Cash from Operations for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $118.7 million.

  • Adma Biologics' Cash from Operations fell 46.89% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 24.50%. This contributed to the annual value of $118.7 million for FY2024, which is 1248.55% up from last year.
  • Latest data reveals that Adma Biologics reported Cash from Operations of $118.7 million as of FY2024, which was up 1,248.55% from $8.8 million recorded in FY2023.
  • Adma Biologics' Cash from Operations' 5-year high stood at $118.7 million during FY2024, with a 5-year trough of -$112.4 million in FY2021.
  • Its 3-year average for Cash from Operations is $22.7 million, with a median of $8.8 million in 2023.
  • Per our database at Business Quant, Adma Biologics' Cash from Operations fell by 10.16% in 2021 and then spiked by 1,248.55% in 2024.
  • Yearly analysis of 5 years shows Adma Biologics' Cash from Operations stood at -$102.0 million in 2020, then dropped by 10.16% to -$112.4 million in 2021, then spiked by 47.04% to -$59.5 million in 2022, then skyrocketed by 114.79% to $8.8 million in 2023, then skyrocketed by 1,248.55% to $118.7 million in 2024.